论文部分内容阅读
目的:观察阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效及不良反应。方法:选择70例活动性乙型肝炎肝硬化的患者,随机分成观察组和对照治疗组各35例。两组均予以常规综合护肝治疗,观察组加用阿德福韦酯片剂10mg/d治疗,连续治疗12个月。分别观察治疗前后的肝功能、HBV血清标志物、HBV-DNA水平变化及Child-Pugh评分。结果:观察组患者的肝功能、HBV血清标志物、HBV-DNA水平变化及Child-Pugh评分,均明显优于对照组患者(P<0.05)。结论:阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效优于常规护肝治疗,且不良反应发生率更低。
Objective: To observe the efficacy and adverse reactions of adefovir dipivoxil in the treatment of active hepatitis B cirrhosis. Methods: Seventy patients with active hepatitis B cirrhosis were randomly divided into observation group (35 cases) and control group (35 cases). Both groups were given conventional comprehensive liver treatment, observation group plus adefovir dipivoxil tablets 10mg / d treatment, continuous treatment for 12 months. The liver function, HBV serum markers, HBV-DNA levels and Child-Pugh scores before and after treatment were observed. Results: The liver function, HBV serum markers, HBV-DNA levels and Child-Pugh scores in the observation group were significantly better than those in the control group (P <0.05). Conclusion: The efficacy of adefovir dipivoxil in the treatment of active cirrhosis of the liver is better than that of conventional liver protection and the incidence of adverse reactions is lower.